P77 L1CAM is an independent predictor of poor survival of endometrial cancer undergoing full lymphadenectomy and adjuvant chemotherapy
Akira Oku(Hokkaido University), Hidemichi Watari(Hokkaido University of Science), Nozomu Kobayashi(National Cancer Center Hospital East), Takashi Mitamura(Sapporo University), Masatoshi Kudo(Kindai University), Tomoyasu Kato(National Cancer Centre Japan), Ayako Nozaki(Hokkaido University), Ryosuke Matsuoka(International University of Health and Welfare), KC Hatanaka(Innovative Clinical Research), Yosuke Konno(Hokkaido University of Science), Yoshihiro Matsuno(Hokkaido University Hospital), Kei Ihira(Hokkaido University), Yutaka Hatanaka(Hokkaido University), Hiroshi Asano(Hokkaido University), Mahito Takeda(Sapporo University)
Cited by 0
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study
|Liver International|2015|1.3k